Side-by-side comparison of AI visibility scores, market position, and capabilities
OpenEvidence hit $100M+ ARR in under a year serving 430K+ US physicians (40% of all US doctors) at $12B valuation ($700M raised); fastest-growing physician AI platform, founded 2022 Miami.
OpenEvidence is an AI clinical evidence platform founded in 2022 and headquartered in Miami, Florida. Built specifically for physicians, the platform applies large language models trained on peer-reviewed medical literature to deliver instant, evidence-backed answers to clinical questions at the point of care. Its founding mission is to democratize access to the best available medical evidence so that every physician can practice at the highest standard, regardless of institution or specialty.\n\nThe platform aggregates and synthesizes peer-reviewed studies, clinical guidelines, and drug databases, presenting structured answers with citations that meet physician-grade accuracy standards. Unlike general-purpose AI assistants, OpenEvidence is purpose-built for clinical workflows. It is free to use for physicians, with monetization routed through pharmaceutical and healthcare industry partners who value the platform's direct access to practicing clinicians.\n\nOpenEvidence has achieved remarkable traction, reaching over 430,000 US physicians — approximately 40% of the entire US physician population — making it the fastest-growing physician AI platform on record. The company crossed $100M ARR in under a year from launch and earned a $12 billion valuation on $700 million in total funding. This trajectory places OpenEvidence among the fastest-scaling healthcare AI companies globally and signals a structural shift toward AI-assisted clinical decision-making at the point of care.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.